Sleep Clinical Trial
— CICAFFOfficial title:
Influence of Caffeine Consumption on the Human Circadian System: Neurobehavioral, Hormonal and Cerebral Mechanisms
Verified date | June 2022 |
Source | Psychiatric Hospital of the University of Basel |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Surveys indicate that 85% of the adult population consume caffeine on a daily basis. Caffeine acts on sleep homeostatic mechanisms by antagonizing the sleep factor adenosine. Whether and how caffeine also impacts on the circadian regulation of sleep and -wakefulness is fairly unexplored. This study quantifies the influence of regular caffeine intake and its cessation on circadian promotion of sleep and wakefulness, on circadian hormonal markers, well-being, neurobehavioral performance and associated cerebral mechanisms. The knowledge is expected to contribute important insights on recent societal changes in sleep-wake behavior (e.g., shorter sleep duration and delayed sleep phase) and the related increase in people suffering from sleep problems.
Status | Completed |
Enrollment | 20 |
Est. completion date | December 17, 2017 |
Est. primary completion date | October 8, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 35 Years |
Eligibility | Inclusion Criteria: - Self-reported caffeine consumption: 300 mg - 600 mg daily - 18-35 years old - Healthiness Exclusion criteria based on chronic or debilitating medical conditions: Normal current health was established based on questionnaires, screenings of urine, and examination by the physician in charge. Given the wide range of illnesses encountered in medical practice, we only list those that were certainly reasons of exclusion: - Diseases of somatic origin: Cardiovascular-, respiratory-, gastrointestinal-, hematopoietic- visual- and immune system diseases, kidney and urinary tract, endocrine and metabolic diseases, neurologic diseases, infectious diseases, allergies (e.g. skin allergies, acute hay fever), thrombocytopenia or other dysfunction of the blood platelets. - Sleep disorders: Narcolepsy, sleep apnea (apnea index >10), periodic limb movements (PLMS >15), insomnia (polygraphically recorded sleep efficiency <70 %), hypersomnia, usual time in bed not between 6-9 h (assessed by [101]). - Chronobiologic disorders: Hypernychthemeral sleep/wake cycle, delayed sleep phase syndrome (waketime >2 h later than desired, or habitually after 10 am), advanced sleep phase syndrome (waketime >2 h earlier than desired or habitually before 5 am). - Drug/alcohol use, except caffeine: Volunteers must be drug-free (including nicotine and alcohol) for the entire duration of the study, with no history of drug (excluding caffeine) or alcohol dependency. Exclusion criteria based on to the study requirements: - Self-reported caffeine consumption: < 300 mg and > 600 mg daily (as estimated from mean caffeine content per serving of caffeine containing beverages and food) - Body Mass Index (BMI) range: <18 and >26 - Participation in other clinical trials <3 months prior to study begin - Shift work <3 months prior to study begin - Transmeridian travel (>2 time zones) <1 month prior to study begin - Extreme chronotype (Morningness-Eveningness Questionnaire <30 or >70) - Inability to follow procedures - Insufficient knowledge of project language (German) Exclusion criteria based on MRI safety: - Metallic prosthesis or metallic implants or non-removable objects on the body (e.g. splinters, piercings) - Tattoos with larger diameter than 10 cm - Tattoos above the shoulder area - Claustrophobia - Contraceptive coil |
Country | Name | City | State |
---|---|---|---|
Switzerland | UPK Basel | Basel | Basel Stadt |
Lead Sponsor | Collaborator |
---|---|
Psychiatric Hospital of the University of Basel | Swiss National Science Foundation |
Switzerland,
Lin YS, Weibel J, Landolt HP, Santini F, Garbazza C, Kistler J, Rehm S, Rentsch K, Borgwardt S, Cajochen C, Reichert CF. Time to Recover From Daily Caffeine Intake. Front Nutr. 2022 Feb 2;8:787225. doi: 10.3389/fnut.2021.787225. eCollection 2021. — View Citation
Lin YS, Weibel J, Landolt HP, Santini F, Meyer M, Brunmair J, Meier-Menches SM, Gerner C, Borgwardt S, Cajochen C, Reichert C. Daily Caffeine Intake Induces Concentration-Dependent Medial Temporal Plasticity in Humans: A Multimodal Double-Blind Randomized — View Citation
Weibel J, Lin YS, Landolt HP, Berthomier C, Brandewinder M, Kistler J, Rehm S, Rentsch KM, Meyer M, Borgwardt S, Cajochen C, Reichert CF. Regular Caffeine Intake Delays REM Sleep Promotion and Attenuates Sleep Quality in Healthy Men. J Biol Rhythms. 2021 — View Citation
Weibel J, Lin YS, Landolt HP, Garbazza C, Kolodyazhniy V, Kistler J, Rehm S, Rentsch K, Borgwardt S, Cajochen C, Reichert CF. Caffeine-dependent changes of sleep-wake regulation: Evidence for adaptation after repeated intake. Prog Neuropsychopharmacol Bio — View Citation
Weibel J, Lin YS, Landolt HP, Kistler J, Rehm S, Rentsch KM, Slawik H, Borgwardt S, Cajochen C, Reichert CF. The impact of daily caffeine intake on nighttime sleep in young adult men. Sci Rep. 2021 Feb 25;11(1):4668. doi: 10.1038/s41598-021-84088-x. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sleep polysomnography in normal baseline sleep | Electrophysiological activities were measured by electroencephalography during sleep. Spectral analysis was performed using a Fast-Fourier transformation to quantify delta (0.75 - 4.5 Hz), theta (4.5 - 8 Hz), alpha (8 - 12 Hz), and sigma (12 - 16 Hz), and beta (16 - 32 Hz) power density . Sleep stages, i.e., non-rapid eye-movement (NREM) stage 1, NREM2, NREM3, NREM4, and REM sleep were determined by visual scoring per 30-second epoch in accordance with the guideline of American Academy of Sleep Medicine (AASM).Sleep stages were reported relative to total sleep time. Duration of sleep latencies was also reported. | First 8-hour nighttime sleep on the laboratory evening (Day 9) | |
Primary | Sleep polysomnography in an evening nap | Electrophysiological activities were measured by electroencephalography during the sleep. Spectral analysis was performed using a Fast-Fourier transformation to quantify delta (0.75 - 4.5 Hz), theta (4.5 - 8 Hz), alpha (8 - 12 Hz), and sigma (12 - 16 Hz), and beta (16 - 32 Hz) power density . Sleep stages, i.e., non-rapid eye-movement (NREM) stage 1, NREM2, NREM3, NREM4, and REM sleep were determined by visual scoring per 30-second epoch in accordance with the guideline of American Academy of Sleep Medicine (AASM).Sleep stages were reported relative to total sleep time. Duration of sleep latencies was also reported. | approx. 13.5-hour after wake-up time on the laboratory day (Day 10) | |
Primary | Sleep polysomnography in a recovery sleep | Electrophysiological activities were measured by electroencephalography during the sleep. A Fast-Fourier Transformation was used to quantify slow wave activities (0.75 - 4.5 Hz), theta (4.5 - 8 Hz), alpha (8 - 12 Hz), and beta (12 - 16 Hz), and sleep stages, i.e., non-rapid eye-movement (NREM) stage 1, NREM2, NREM3, NREM4, and REM sleep were determined by visual scoring through each 30-second epoch in accordance with the guideline of American Academy of Sleep Medicine (AASM). | Second 8-hour nighttime sleep following 20-hour wakefulness on the laboratory day (Day 10) | |
Primary | Wake-EEG | Electrophysiological activities during wakefulness measured by electroencephalography during the sleep. A Fast-Fourier Transformation was used to quantify slow wave activities (0.75 - 4.5 Hz), theta (4.5 - 8 Hz), alpha (8 - 12 Hz), and beta (12 - 16 Hz). | 14 measurements: (Day 9) -130, -20 minutes to the bedtime. (Day 10) +20, +140, +260, +370, +490, +600, +725, +867, +945, +1065, +1180, +1250 minutes after awakening. | |
Primary | Melatonin levels | The oscillation of melatonin levels across 43-hour laboratory stay were measured from the 33 salivary samples. The dim-light melatonin onset (DLMO) and average secretion level were analyzed and compared among three conditions. | 33 samples: (Day 9) -310,-250,-190,-140,-110,-80,-50,-10 minutes to the bedtime. (Day 10) + 50,+110,+170,+230,+290,+350,+400,+460,+515,+580,+610,+670,+700,+735,+765,+935,+965,+995,+1055,+1075,+1115,+1145,+1170, +1190,+1250 after awakening. | |
Primary | Subjective sleepiness | Participants were asked to assess their perceived sleepiness by Karolinska Sleepiness Scale (KSS), where they answered 1 for very alert and 9 for very sleepy. | 33 samples: (Day 9) -310,-250,-190,-140,-110,-80,-50,-10 minutes to the bedtime. (Day 10) + 50,+110,+170,+230,+290,+350,+400,+460,+515,+580,+610,+670,+700,+735,+765,+935,+965,+995,+1055,+1075,+1115,+1145,+1170, +1190,+1250 after awakening. | |
Primary | Vigilance | Vigilance was assessed by psychomotor vigilance tasks (PVT). Participants were asked to respond to each stimulus showing on a screen as soon as they can by keying down. The reaction times and lapses were used to indicate the vigilance. | 7 measurements: (Day 9) -160 minutes to the bedtime. (Day 10) +95, +335, +560, +795, +1040, +1235 minutes after awakening. | |
Primary | Vigilance-related blood oxygen level-dependent activities | Regional brain activation is measured by echo-planar-imaging (EPI) sequence in a 3T fMRI scanner during a psychomotor vigilance task (PVT). | +795 minutes after waking up on the laboratory day (Day 10) | |
Primary | Working memory-related blood oxygen level-dependent activities | Regional brain activation is measured by echo-planar-imaging (EPI) sequence in a 3T fMRI scanner during a working memory task (N-back). | +775 after waking up on the laboratory day (Day 10) | |
Primary | Blood oxygen level-dependent activities in resting state | Functional connectivity is measured by echo-planar-imaging (EPI) sequence in a 3T fMRI scanner during an eye-open resting state. | approx.13.7 hours after waking up on the laboratory day (Day 10) | |
Secondary | Cerebral blood flow | Arterial Spin Labeling sequence was used to measure the changes in cerebral blood flow induced by caffeine intake and caffeine cessation. | approx. 13.5 hours after waking up on the laboratory day (Day 10) | |
Secondary | Caffeine concentrations | Caffeine concentrations were measured from salivary and perspiratory samples. | 12 samples: (Day 9) -185 minutes to the bedtime. (Day 10) +15, +120, +240, +300, +480, +590, +735, +825, +975, +1085, +1195 minutes after awakening. | |
Secondary | Working memory | Working memory capacity was measured by N-Back tasks, where participants had a high workload condition (3-back) and a low workload condition (0-back). | 7 measurements: (Day 9) -140 minutes to the bedtime. (Day 10) +75, +315, +540, +775, +1020, +1215 minutes after awakening. | |
Secondary | Sleep diary | A daily log was used to record the participant's bed- and wakeup time, self-report sleep quality, tiredness, and activities during the day including caffeine intake. | Upon wake-up and bedtime during the ambulatory parts (Day1 to Day8 and Day11 to Day17) | |
Secondary | Actimetry | Participants wore an actiwatch to record the muscle tone in order to track the body movement and sleep-wake behaviors constantly throughout the entire study. | Constant recording from Day1 to Day17. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04044495 -
Sleep, Rhythms and Risk of Alzheimer's Disease
|
N/A | |
Recruiting |
NCT06079853 -
Nurse Suicide: Physiologic Sleep Health Promotion Trial
|
N/A | |
Completed |
NCT05017974 -
Research on Improving Sleep During Pregnancy
|
N/A | |
Recruiting |
NCT05206747 -
Ottawa Sunglasses at Night for Mania Study
|
N/A | |
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT04513743 -
Ultra Long-Term Sleep Monitoring Using UNEEG™ Medical 24/7 EEG™ SubQ
|
N/A | |
Completed |
NCT03251274 -
Bath Machine on Sleep Quality in Nursing Home
|
N/A | |
Completed |
NCT04102345 -
Lavender vs Zolpidem Sleep Quality During Diagnostic PSG
|
Early Phase 1 | |
Completed |
NCT03725943 -
Comparison of Dreem to Clinical PSG for Sleep Monitoring in Healthy Adults
|
N/A | |
Active, not recruiting |
NCT05062161 -
Sleep Duration and Blood Pressure During Sleep
|
N/A | |
Completed |
NCT04562181 -
Consistency Evaluation of the qCON, qNOX Indices and Bispectral Index
|
N/A | |
Completed |
NCT05576844 -
Ai Youmian (Love Better Sleep) for People Living With HIV
|
N/A | |
Completed |
NCT05102565 -
A Dyadic Telehealth Program for Alzheimer's Patients/Caregivers
|
N/A | |
Completed |
NCT04688099 -
Synovial Fluid Sleep Study
|
||
Recruiting |
NCT04171245 -
Prescribing Laughter for Sleep and Wellbeing in UAE University Students
|
N/A | |
Completed |
NCT03758768 -
The Effects of a Blue Monochromatic Light Intervention on Evening-type Individuals' Sleep and Circadian Rhythms
|
N/A | |
Completed |
NCT03163498 -
Evaluation of Sleep Pattern and Mood Profile in Hypertensive Patients
|
||
Completed |
NCT04093271 -
Investigating the Efficacy of Rest-ZZZ Formula in Healthy Participants With Difficulty Falling Asleep or Staying a Sleep
|
Phase 1 | |
Completed |
NCT03673397 -
The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression
|
N/A | |
Completed |
NCT04120363 -
Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations
|
Phase 4 |